8-K: Microbot Medical's LIBERTY System Gains Visibility at Summit

Microbot Medical Inc. announced its CEO, Harel Gadot, will be a featured panelist at The Surgical Disruptive Technology Summit, highlighting the LIBERTY Endovascular Robotic System.

Summary

• Harel Gadot, CEO, President & Chairman of Microbot Medical Inc., will be a featured panelist at The Surgical Disruptive Technology Summit, part of SAGES NBT Innovation Weekend.
• The summit is taking place from February 19-21, 2026, in Houston, TX.
• Mr. Gadot will participate in a dedicated panel titled "Endovascular Therapeutics: AI and Robotics."
• This platform will be used to highlight the unique features of the LIBERTY Endovascular Robotic System and establish it as a new category of surgical robotics.
• The company believes growing confidence in AI and robotic innovations in endovascular procedures will support accelerated adoption of LIBERTY.
• LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
• The system is designed for precise vascular navigation, aiming to reduce radiation exposure and physical strain.
• Limited market release of LIBERTY commenced in late 2025.
• A full market release is planned for the Society of Interventional Radiology (SIR) conference in April 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, enhancing market visibility and reinforcing the commercialization pathway for the LIBERTY system, though it doesn't present new financial metrics or immediate revenue-generating events.

Positives

• CEO Harel Gadot's participation as a featured panelist at a prominent industry summit enhances market visibility for the LIBERTY Endovascular Robotic System.
• The dedicated panel on "Endovascular Therapeutics: AI and Robotics" provides a strategic platform to showcase LIBERTY's unique features and position it as a new class of surgical robotics.
• LIBERTY is highlighted as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, indicating a competitive advantage.
• The system's design aims to reduce radiation exposure and physical strain, improving safety and ergonomics for medical professionals.
• The company anticipates accelerated adoption of LIBERTY due to growing confidence in AI and robotic innovations in endovascular procedures.
• The planned full market release at the SIR conference in April 2026 is a significant step towards broader commercialization and market penetration.

Risks

• Market conditions.
• Risks inherent in the commercialization of the LIBERTY Endovascular Robotic System and in the development of future versions or applications.
• Uncertainty in the results of regulatory pathways and regulatory approvals.
• Uncertainty resulting from political, social, and geopolitical conditions, particularly changes in personnel or processes at the FDA and announcements of tariffs on imports into the U.S.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Maintenance of intellectual property rights.

Future Outlook

Microbot Medical anticipates accelerated adoption of its LIBERTY Endovascular Robotic System, driven by increasing confidence in AI and robotic innovations within endovascular procedures. The company plans a full market release in April 2026, aiming to deepen market adoption and redefine endovascular care.

Management Comments

• "We believe that the continued emergence of the LIBERTY System, together with the expanding range of procedures performed to date, is redefining how endovascular care is delivered today and how it will be delivered years ahead."
• "The dedicated session around the Endovascular space serves as another proof of the opportunities it holds."
• "LIBERTY's distinct advantages, including its single-use, compact robotic design, are intended to remove many of the barriers that have historically limited the broader adoption of surgical robotics."
• "We believe this positions LIBERTY as a new class of surgical robotics, expanding access to advanced robotics and enabling high quality care for a broader range of health systems and patients."

Industry Context

StockSavvy.ai notes that Microbot Medical's participation in The Surgical Disruptive Technology Summit aligns with a broader industry trend towards integrating AI and robotics into minimally invasive surgical procedures, particularly in the endovascular space. This move positions LIBERTY within a growing market focused on enhancing precision, safety, and accessibility in complex medical interventions.

Comparison to Industry Standards

• LIBERTY is highlighted as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, suggesting a unique market position compared to multi-use or non-remotely operated systems from competitors.
• The focus on reducing radiation exposure and physical strain for medical professionals addresses key ergonomic and safety concerns prevalent across the surgical robotics industry.
• The company aims to establish a "new category of surgical robotics" by removing historical barriers to adoption, potentially differentiating it from established players like Intuitive Surgical (da Vinci system) which primarily focuses on general surgery, or other emerging robotic platforms in specific niches.

Stakeholder Impact

• Shareholders: Increased visibility and potential for future market adoption could positively impact long-term value, though no immediate financial impact is detailed.
• Medical Professionals: The LIBERTY system aims to reduce radiation exposure and physical strain, potentially improving working conditions and safety for surgeons and staff.
• Patients: The system is designed to enhance access, safety, and clinical outcomes across vascular care.
• Health Systems: The single-use, compact robotic design aims to remove barriers to broader adoption, potentially making advanced robotics more accessible to a wider range of health systems.

Next Steps

• Harel Gadot to serve as a featured panelist at The Surgical Disruptive Technology Summit, February 19-21, 2026.
• Showcase LIBERTY system at the dedicated "Endovascular Therapeutics: AI and Robotics" panel.
• Full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026.
• Deepen market adoption following the full market release.

Key Dates

Recommendation

The announcement provides positive updates on market visibility and the commercialization roadmap for the LIBERTY system, reinforcing the company's strategic direction. However, it lacks immediate financial catalysts or new, unexpected developments that would warrant a "buy" recommendation. The identified risks and the early stage of full market release suggest a "hold" position is appropriate for investors awaiting more concrete financial outcomes from the commercialization efforts.

Keywords

Microbot Medical, LIBERTY System, Endovascular Robotics, Surgical Robotics, Medical Devices, FDA Cleared, AI in Surgery, Robotic Surgery, Peripheral Endovascular Procedures, Healthcare Technology, MBOT